Trucco, Federica
Salmin, Francesca
Lizio, Andrea
Coratti, Giorgia
Albamonte, Emilio
Frisoni, Maria Chiara
Mauro, Luca
Carraro, Elena
Palazzo, Giovanni
Lops, Jessica
Cattaneo, Camilla
Pozzi, Susanna
Casiraghi, Jacopo
Di Bari, Alessandra
Berti, Beatrice
Stanca, Giulia
Ricci, Martina
Pane, Marika
Heatwole, Chad
Dilek, Nuran
Mercuri, Eugenio
Sansone, Valeria Ada
Funding for this research was provided by:
Biogen
Università degli Studi di Milano
Article History
Received: 13 January 2023
Accepted: 21 April 2023
First Online: 8 June 2023
Declarations
:
: Chad Heatwole receives royalties for the use of multiple disease specific instruments. He has provided consultation to Biogen Idec, Ionis Pharmaceuticals, aTyr Pharma, AMO Pharma, Acceleron Pharma, Cytokinetics, Expansion Therapeutics, Harmony Biosciences, Regeneron Pharmaceuticals, Astellas Pharmaceuticals, AveXis, Recursion Pharmaceuticals, IRIS Medicine, Inc., Takeda Pharmaceutical Company, Scholar Rock, Avidity Biosciences, Novartis Pharmaceuticals Corporation, SwanBio Therapeutics, Neurocrine Biosciences, and the Marigold Foundation. He receives grant support from the Department of Defense, Duchenne UK, Parent Project Muscular Dystrophy, Recursion Pharmaceuticals, Swan Bio Therapeutics, the National Institute of Neurological Disorders and Stroke, the Muscular Dystrophy Association, the Friedreich’s Ataxia Research Alliance, Cure Spinal Muscular Atrophy, the Amyotrophic Lateral Sclerosis Association, the University of Miami, Novartis Pharmaceuticals Corporation, and the Michael J. Foxx Foundation. He is the director of the University of Rochester’s Center for Health and Technology.